More research is needed to further define these mechanisms; however, future therapeutic strategies might include: overexpression of Serpina1a and increased levels of HGF, upregulation of the GH pathway and increased MUP expression, and increased LCN2 expression to limit intestinal injury following cholestasis. This evidence concerns the gene LCN2 and cholestasis.